当前位置：
X-MOL 学术
›
Clin. Exp. Allergy
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Matching‐Adjusted Comparison of Oral Corticosteroid Reduction in Asthma: Systematic Review of Biologics
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-03-20 , DOI: 10.1111/cea.13561 Arnaud Bourdin 1, 2 , Don Husereau 3, 4 , Nicolas Molinari 5 , Sarowar Golam 6 , Mohd Kashif Siddiqui 7 , Leandro Lindner 8 , Xiao Xu 9
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-03-20 , DOI: 10.1111/cea.13561 Arnaud Bourdin 1, 2 , Don Husereau 3, 4 , Nicolas Molinari 5 , Sarowar Golam 6 , Mohd Kashif Siddiqui 7 , Leandro Lindner 8 , Xiao Xu 9
Affiliation
Oral corticosteroid (OCS) treatment for severe asthma is associated with substantial disease burden. Thus, OCS dosage reduction is desirable. Relative efficacy of biologics in reducing OCS treatment for severe, uncontrolled asthma is not fully characterized.
中文翻译：
哮喘中口服皮质类固醇减少的匹配调整比较：生物制剂的系统评价
严重哮喘的口服皮质类固醇 (OCS) 治疗与大量疾病负担相关。因此，需要减少 OCS 剂量。生物制剂在减少 OCS 治疗严重、不受控制的哮喘方面的相对功效尚未完全表征。
更新日期：2020-03-20
中文翻译：
哮喘中口服皮质类固醇减少的匹配调整比较：生物制剂的系统评价
严重哮喘的口服皮质类固醇 (OCS) 治疗与大量疾病负担相关。因此，需要减少 OCS 剂量。生物制剂在减少 OCS 治疗严重、不受控制的哮喘方面的相对功效尚未完全表征。
京公网安备 11010802027423号